CD4+ T细胞中IL-10与IL-17表达在糖皮质激素难治性免疫性血小板减少症(ITP)中发生改变
这项前瞻性队列研究将ITP患者CD4+ T细胞在地塞米松(Dex)存在或不存在下培养,用流式细胞术定量胞内细胞因子表达,并与糖皮质激素临床反应比较;Dex培养后IL-10与IL-17表达比值可区分完全(n=33)、部分(n=12)与无反应(n=11)患者(P=.002),并在自身免疫性葡萄膜炎中重复(完全反应n=14,无反应n=22;P=.01)。
要点
- Dex培养后CD4+ T细胞IL-10/IL-17比值可区分ITP患者糖皮质激素完全、部分与无反应(P=.002)。
- 该比值在自身免疫性葡萄膜炎完全反应(n=14)与无反应(n=22)患者间也有区分(P=.01)。
- 临床糖皮质激素治疗失败的ITP患者CD4+ T细胞中IL-10表达相对缺失而IL-17表达持续存在。
核心结论
- 临床糖皮质激素治疗失败的ITP患者CD4+ T细胞中IL-10表达相对缺失而IL-17表达持续存在。
- 该观察有望帮助理解糖皮质激素治疗ITP的机制,并作为糖皮质激素难治性疾病的生物标志物,可能适用于一系列血液和非血液疾病。
研究设计与样本
- 前瞻性队列研究,将ITP患者CD4+ T细胞在地塞米松(Dex)存在或不存在下培养,用流式细胞术定量胞内细胞因子表达,并与糖皮质激素治疗临床反应比较。
- 同时研究自身免疫性葡萄膜炎对照队列,以评估发现是否仅限于ITP或可能可推广至自身免疫性疾病。
主要发现
- Dex培养后CD4+ T细胞IL-10与IL-17表达比值可区分临床定义糖皮质激素完全反应(n=33)、部分反应(n=12)与无反应(n=11)的ITP患者(P=.002)。
- 该发现在自身免疫性葡萄膜炎患者中重复:完全反应(n=14)与无反应(n=22)患者间有区分(P=.01)。
关键数值与推荐
- ITP患者按糖皮质激素临床反应分为完全反应(n=33)、部分反应(n=12)和无反应(n=11)。
- 自身免疫性葡萄膜炎患者分为完全反应(n=14)和无反应(n=22)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Corticosteroids remain the first-line treatment for patients with immune thrombocytopenia (ITP). However, 20% to 30% of patients do not respond to treatment at tolerable doses. This variation in corticosteroid efficacy is replicated in other autoimmune diseases and may have an adaptive immune basis. OBJECTIVE: To test the hypothesis that CD4+ T-cell responses to corticosteroids are different in patients with clinically defined corticosteroid refractory ITP. METHODS: In this prospective cohort study, CD4+ T cells from patients with ITP were cultured in the presence or absence of dexamethasone (Dex). Intracellular cytokine expression was then quantified by flow cytometry and compared with patients' clinical response to corticosteroid treatment. A control cohort of patients with autoimmune uveitis was also studied to evaluate whether our findings were limited to ITP or are potentially generalizable across autoimmune diseases. RESULTS: The ratio of interleukin (IL)-10 to IL-17 expression following CD4+ T cell culture with Dex was able to discriminate between ITP patients with a clinically defined complete (n = 33), partial (n = 12) or nonresponse (n = 11) to corticosteroid treatment (P = .002). These findings were replicated in patients with autoimmune uveitis (complete response n = 14, nonresponse n = 22; P = .01). CONCLUSIONS: There is a relative abrogation of IL-10 and persistence of IL-17 expression in the CD4+ T cells of patients who clinically fail corticosteroid therapy. This observation has potential to inform both our mechanistic understanding of the action of corticosteroids in the treatment of ITP, and as a biomarker for steroid refractory disease, with potential application across a range of hematological and nonhematological conditions.
引用
- Stimpson ML, Lait PJP, Schewitz-Bowers LP, et al. IL-10 and IL-17 expression by CD4+ T cells is altered in corticosteroid refractory immune thrombocytopenia (ITP). J Thromb Haemost. 2020. PMID: 32574429. doi:10.1111/jth.14970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。